TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life (QOL) in Female Patient With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis: Schizophrenia (DSM-IV)~2. Female, Age: between 18-60 years~3. Who either need first time treatment with antipsychotic drug or recently~4. Sign written informed consent~Exclusion Criteria:~1. Taking other psychiatric medications during last 30 days~2. Refractory schizophrenia~3. A current medical illness associated with sexual dysfunction~4. Previous history of no response to quetiapine or risperidone treatment~5. Previous enrolment or randomisation of treatment in the present study.~6. Participation in a clinical study during the last 90 days.~7. Pregnancy~8. Alcohol or substance abuser

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial Infarction Complicated With Cardiogenic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myocardial infarction complicated with cardiogenic shock~* Patient without contraindication to IABP or ECLS-Impella~Exclusion Criteria:~* Patient with refractory cardiogenic shock~* Reperfusion \> 24 hours after the pain begins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): IABP, inotropic drugs, antiplatelet agents according to site habits.
- Experimental (Type: EXPERIMENTAL): ECLS +/- IABP, inotropic drugs, antiplatelet agents according to site habits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Objective Sleep Duration on Blood Glucose Control in Type 1 Diabetes Adult Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient affiliated to Social Security~* Written consent to participate to the study~* Ambulatory medical follow-up~* Patient with type 1 diabetes, defined by the criteria of the American Diabetes Association in 1997, stable (no ketoacidosis episode or hypoglycaemia with loss of consciousness requiring the intervention of a third person, during the previous month)~Exclusion Criteria:~* Underage patient, major patient under guardianship or protected by the Law~* Pregnant, parturient or breastfeeding woman~* Person with no freedom (prisoner), person hospitalized without consent and not protected by the Law~* Non-stabilized diabetes with at least one ketoacidosis episode or hypoglycaemia with loss of consciousness requiring the intervention of a third person, during the previous month.~* Bedridden person or person with mobility impairment.~* Patient already hospitalized at enrolment time~* Patient whose physical or psychological health could interfere with obtention of informed consent and compliance to the protocol (especially answers to the questionnaires)~* Terminally-ill patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: EdemaWear to Reduce Edema in Hospitalized Patients With CVI:

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* history of CVI (Clinical classification 1-5), with \> 2+ edema of the lower legs,~* \> 2+ peripheral pulses (popliteal, dorsalis pedis \[DP\], and posterior tibial \[PT\]) or audible biphasic / triphasic Doppler signal, if pulses not palpable.~Exclusion Criteria:~* open venous stasis ulcer(s) or other wounds on lower legs~* lymphedema or risk factors for lymphedema~* acute heart failure with active management~* known deep vein thrombosis (DVT) with subtherapeutic anticoagulation~* peripheral arterial disease (PAD) with reduced / absent pulses~* known or suspected inferior vena caval (IVC) compression~* circumference of lower leg \< 45 cm or \> 115 cm (size limits of small and extra-large EdemaWear®)~* severely altered mental status or lacking capacity to consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edema Wear (Type: EXPERIMENTAL): Edema Wear fuzzy wale compression garment worn on lower extremities continuously for 5 days or until discharge if less than 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* seropositive for Toxoplasma gondii (for patient and parents)~* Infection with genotype II (for patient and parents)~* ocular toxoplasmosis recurrences \>5 (patients only)~Exclusion Criteria:~* Parents seronegative for T. gondii infection~* Infection with others genotypes than type II

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- seropositive for Toxoplasma gondii (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with metastatic or recurrent breast cancer.~* Have been previously treated with both an anthracycline and a taxane.~* Have not received more than two prior chemotherapy treatment programs.~* Have stopped any antitumoral hormonal treatment before you enroll in this study.~* Have a negative pregnancy blood test if menstruating or capable of becoming pregnant. You must use an approved birth control method during the study and for 3 months after stopping study treatment.~Exclusion Criteria:~* Cannot follow the study procedures (for example, you cannot swallow tablets).~* Are receiving another treatment for your cancer.~* Have received another experimental drug in the last 4 weeks.~* Have had serious heart disease within last 6 months.~* Are pregnant or breast-feeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine + Enzastaurin (Type: EXPERIMENTAL): None
- Capecitabine + Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Emdogain and Straumann Bone Ceramic in Infrabony Defects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females must be at least 18 years and not more than 75 years of age~* The patient will have to be able to understand and sign the informed consent prior to starting the study.~* The patient also will have to have the ability and the willingness to comply with all study requirements.~* The patients will be in good general health without any systemic diseases.~* The teeth included in the study will be mandibular molars, maxillary and mandibular premolars, and canines.~* The patients will have to have at least one defect with pocket depth ≥ 5 mm.~* Intra-bony defects will have to have 1 or 2-wall morphology (at least 2/3 of the defect).~* Depth of the intrabony component of at least 3 mm~* The selected sites will have to have vertical intra-bony component ≥ 3 mm and an angle ≥ 30 degrees as assessed from standardized intra-oral radiographs.~* Oral hygiene parameters: Plaque Index (PI) ≤ 20 % and bleeding on probing (BoP) ≤ 20%~Exclusion Criteria:~* Heavy smokers: more than 20 cigarettes per day~* Mucosal diseases such as erosive lichen planus~* History of local radiation therapy~* Presence of oral lesions (such as ulceration, malignancy)~* Teeth with untreated endodontic or cardiologic problems~* Physical handicap that will interfere with patient's ability to exercise good oral hygiene on a regular basis.~* Patients presenting antibiotic treatment within the 3 months preceding the surgical procedure.~* Patients using anti-inflammatory drugs on a regular basis.~* Intra-bony defects with a 3-wall morphology.~* Intra-bony defects with furcation involvement.~* Incisors and maxillary molars, will be excluded.~* Alcoholism or chronically drug abuse causing systemic compromize~* Medical conditions requiring prolonged use of steroids~* Current pregnancy at the time of recruitment and/or breastfeeding women.~* Conditions or circumstances, in the opinion of the investigator, which could represent a general contra-indication for surgical procedure or would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Emdogain PLUS (Type: ACTIVE_COMPARATOR): Straumann Emdogain in combination with Straumann BoneCeramic
- Autogenous bone (Type: ACTIVE_COMPARATOR): Autogenous bone from the patient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has been receiving warfarin therapy for at least 1 week and is planned to continue this treatment for at least one month post-procedure~* The patient will have elective implantation or replacement of a pacemaker or ICD~Exclusion Criteria:~* Age \<18 years~* Previous stroke~* Stroke risk (CHADS2) score of 0 or 1 in patients with atrial fibrillation as the only indication for anticoagulation~* Creatinine clearance (CrCl) \<30 mL/min~* Surgery planned for a Monday or a day after a holiday~* Patient unsuitable for the study as assessed by the investigator (e.g., psychiatric disorder, history of non-compliance)~* Failure to obtain written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bridged regimen (Type: ACTIVE_COMPARATOR): Bridged regimen Warfarin therapy is stopped for 5 days before surgery and restarted in the evening of surgery at double the usual dose for two days. Bridging with low-molecular-weight heparin at therapeutic dose is given for 2½ days before surgery.
- Tapered warfarin regimen (Type: EXPERIMENTAL): Tapered warfarin regimen Warfarin is given at half the usual maintenance dose for 3-6 days before surgery depending on the INR at the baseline visit. A double dose is given in the evening of surgery. No bridging with LMWH is used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Test-Retest Reliability in DETECT

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age \> or = 16~* eligible for active participation during the National Collegiate Athletic Association (NCAA) season or member of the 2011 - 2012 or 2012-2013 club team~* Participation in a non or minimal contact sport~Exclusion Criteria:~* \< age 16~* history of concussion in the previous 6 months~* any of the following: learning disabilities, attention deficient disorder, attention deficit hyperactivity disorder, depression or other psychiatric disorder, sleep apnea, seizure disorder, migraine headaches, previous central nervous system (CNS) surgery~* chronic drug or alcohol use; or drug or alcohol use with the previous 24 hours~* inability to complete the study protocol (90 days)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Neurophysiological Monitoring Detection of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
All adult subjects who have a subarachnoid hemorrhage from a ruptured aneurysm and require high levels of sedation, or a poor neurologic exam and mechanical ventilation will be eligible for the study. Hunt and Hess Grade 4 and 5(worst grades; highest mortality; highest level of dependence if survived) subarachnoid hemorrhage subjects by definition have a severely depressed exam, and will require intubation and mechanical ventilation. Those subjects whose respiratory status deteriorates necessitating intubation and high levels of sedation will also qualify.~All subjects who have subarachnoid hemorrhage from undetermined source, such as angiogram negative subarachnoid hemorrhage, those who have a reliable neurological exam such as Hunt and Hess grade 1-3 subarachnoid hemorrhage subjects, and those who are intubated, but require minimal sedation and therefore have a consistent neurological exam will be excluded from the study. Also, any subject that has a body temperature of less then 32 degrees Celsius will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Monitoring (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of an Endoluminal-suturing Device for Endoscopic Gastric Reduction As an Aid for Class I Obesity, or Class II Obesity Without Comorbidity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years ≤ age ≤ 65 years~* Class I obesity (30 \<BMI \<35 kg / m²) or Class II without comorbidity (35 \<BMI \<40 kg / m²)~Exclusion Criteria:~* Achalasia or other disturbance of motility of the esophagus;~* severe esophagitis;~* Peptic ulcer disease;\* uncontrolled diabetes~* Weight loss\> 5% of the total weight over the last 6 months;~* Gastrointestinal stenosis or obstruction;~* Pregnancy, breastfeeding, or desire for pregnancy in the next 18 months;~* Previous bariatric surgery, balloon or other endoscopic therapy of obesity;~* Gastric surgery scheduled within 60 days of surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vertical gastric plication (Type: EXPERIMENTAL): Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic PD~* On a stable medication regimen for at least one month with leg edema occurring after the start of pramipexole or ropinirole and the absence of other possible reasons for discontinuation of pramipexole or ropinirole treatment (e.g. other adverse effects).~Exclusion Criteria:~* Pregnancy~* Breastfeeding~* Women of child bearing age not using a reliable method of contraception~* Coronary disease, abnormal QT interval on electrocardiogram (EKG)~* Diabetes mellitus~* Hepatic disease~* Alcohol abuse~* Renal disease~* Edema of one leg only~* Presence of other conditions possibly causing leg edema

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has thrombocytopenia associated with chronic liver disease and is planned for or underwent treatment with avatrombopag prior to a procedure~* Patient provides written informed consent~Minimum Data for Retrospective Enrollment~* Platelet count from approximately 7 days prior to starting avatrombopag~* Platelet count on Procedure Day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Frozen-thawed Embryo Transfer in a Natural Cycle: hCG Triggering Versus LH Home Test

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Patient with IVF or ICSI cycle and therefore having frozen-thawed embryos~* Regular menstruation cycle~* Patient's willingness to participate in the study~Exclusion Criteria:~* - Irregular menstrual cycle demanding preparing endometrium with hormones for frozen-thawed embryo~* No frozen embryos after IVF cycle~* Allergy to Pregnyl® or some of its ingredients in the medication or other contraindications due to Pregnyl®

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Pregnyl (Human chorionic gonadotropin) (Type: EXPERIMENTAL): In this group, patients have natural cycle in frozen-thawed embryo transfer and the ovulation is confirmed by administration of hCG (Pregnyl® 5000 IU). The day of transferring embryo is depending on the day of administration of hCG and the age of the embryo. The day zero day is defined by ovulation triggered by hCG.
- Home ovulation test (Type: OTHER): The patients randomized to the LH surge group perform the ovulation home test daily from the urine. Thus, the ovulation in this group is corfimed by the urine test. The day of transferring embryo is depending on the positive ovulation test and the age of the embryo. The day zero day is defined by positive ovulation test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Thrombin Generation and Thromboelastography in Non-overt DIC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Systemic inflammatory response syndrome with known or suspected infection~* Patient to be admitted to the hospital~Exclusion Criteria:~* Diabetic ketoacidosis, Hemophilia, weight \< 25 kg, use of hemostatic agents prior to entry.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues